Trial Profile
A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 18 Jul 2012 Actual patient number changed from 156 to 157 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
- 22 Jun 2012 Actual patients number is 156 as reported by ClinicalTrials.gov.